According to EGIR, the insulin resistance syndrome should be diagnosed if insulin resistance is observed with two or more of the following abnormalities: fasting plasma glucose concentrations ≥6.1 mmol/l without diabetes, blood pressure ≥140/90 mmHg or treatment for elevated blood pressure, triglyceride levels >2.0 mmol/l (177 mg/dl) or treatment for elevated triglycerides and/or HDL cholesterol levels <1.0 mmol/l (88 mg/dl) or treatment for reduced HDL cholesterol levels, or an increased waist circumference (≥94 cm for men and ≥80 cm for women). EGIR criteria for blood pressure and dyslipidemia were drawn from the report of the Second Joint Task Force of European and other Societies on Coronary Prevention, which suggested that proposed cut-off values for blood pressure, triglyceride, and HDL cholesterol levels were associated with increased coronary heart disease risk (9). Regarding obesity criteria, EGIR did not incorporate BMI in its diagnosis variables because the association between BMI and insulin resistance is not very clear, obesity being heterogeneous and not always associated with insulin resistance (10). In addition, waist-to-hip ratio was omitted and waist circumference included since it is a better correlate of intra-abdominal adiposity than waist-to-hip ratio (5). EGIR also excluded microalbuminuria from its criteria since the relationship between microalbuminuria and insulin resistance is not clear.

Role of the Dysregulated Endocannabinoid System in Determining Cardiometabolic Risk by Vincenzo Di Marzo, PhD
More
What is the role of low HDL cholesterol in the elevated CHD risk of metabolic syndrome patients? By Philip J. Barter, MBBS, FRACP, PhD
More
Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2008;32:283-91
More
Schematic representation of how smoking might add to several mechanisms linking obesity to cardiovascular disease
More